Hyperthermic Synergy: Whole-Body Hyperthermia (WBH) and Antibiotics in the Treatment of Lyme Disease (Neuroborreliosis)

1. The Mechanism by Which WBH Enhances Antibiotic Efficacy

*Whole-Body Hyperthermia (WBH)* is utilized as an adjuvant therapy for resistant infections, particularly Lyme Disease (Borreliosis), due to its *synergistic effect* with antibiotics [1, 2]. In vitro studies have shown that a slight increase in core body temperature enhances the *susceptibility* of the Borrelia burgdorferi bacterium to key antibiotics, such as *Ceftriaxone* and *Penicillin* [1]. Furthermore, raising the temperature to an extreme fever range directly targets the *thermophilicity of the spirochete* [2].

In Vitro Evidence and Clinical Rationale

• *Increased Bacterial Susceptibility:* Studies indicate that raising the temperature from 36°C to 38°C (within the physiological fever range) can increase the *antibiotic susceptibility* of Borrelia burgdorferi by up to *16-fold* [1]. This is particularly crucial in tissues where high antibiotic concentrations are difficult to achieve (e.g., the blood-brain barrier).
• *Spirochete Thermolability:* The Borrelia burgdorferi bacterium is *thermolabile, meaning it cannot tolerate high temperatures. The *Extreme Hyperthermia* protocol (above 41°C) is applied in specialized clinics to cause *direct damage* and eliminate persistent and cystic forms of the bacteria [2].
• *Immune Activation:* WBH at fever-range levels not only weakens the bacteria but also *activates the host’s immune system*, including macrophages, which are essential for microbial elimination.

2. WBH as an Adjuvant in Chronic Neuroborreliosis

The efficacy of WBH is particularly relevant in Chronic Neuroborreliosis, where the Borrelia bacterium can persist in the nervous system and other hard-to-reach tissues:

• *Enhanced Penetration:* Elevated temperature increases blood flow and the *permeability of cell membranes* and barriers (such as the blood-brain barrier), facilitating the penetration of antibiotics into tissues where access is normally limited.
• *Cystic Targeting:* It is theorized that thermal stress helps disrupt the survival forms (cysts) of Borrelia and the *biofilms* they form, thus increasing their vulnerability to drug action.

Scientific and Clinical References (E-E-A-T)

1. Reisinger E., Wendelin I., Gasser R., Halwachs G., Truschnig M.W., Krejs G. Antibiotics and Increased Temperature against Borrelia burgdorferi In Vitro. Scand J Infect Dis 1996; 28:155-57.
2. Clinical Protocols: Rationale based on the thermolability of Borrelia burgdorferi (susceptible to cell death at temperatures ≥ 41.6°C / 106.8°F) and enhanced drug penetration. (Secondary specialized clinic references, e.g., St. Georg Klinik, Verthermia).